HMGB1 and neuroblastoma: Direct evidence of clinical associations, together with the findings of Treg differentiation due to high HMGB1 levels in NB TME in vitro, supported future investigations which aim to mitigate HMGB1 overexpression in tumors and/or to neutralize secretory HMGB1 in NB TME.